Literature DB >> 31932493

Diverse AR Gene Rearrangements Mediate Resistance to Androgen Receptor Inhibitors in Metastatic Prostate Cancer.

Yingming Li1, Rendong Yang1,2, Christine M Henzler3, Yeung Ho1, Courtney Passow4, Benjamin Auch4, Suzanne Carreira5, Daniel Nava Rodrigues5, Claudia Bertan5, Tae Hyun Hwang6, David A Quigley7,8, Ha X Dang9,10, Colm Morrissey11, Michael Fraser12, Stephen R Plymate13,14, Christopher A Maher9,10, Felix Y Feng7,15, Johann S de Bono5,16, Scott M Dehm17,18,19.   

Abstract

PURPOSE: Prostate cancer is the second leading cause of male cancer deaths. Castration-resistant prostate cancer (CRPC) is a lethal stage of the disease that emerges when endocrine therapies are no longer effective at suppressing activity of the androgen receptor (AR) transcription factor. The purpose of this study was to identify genomic mechanisms that contribute to the development and progression of CRPC. EXPERIMENTAL
DESIGN: We used whole-genome and targeted DNA-sequencing approaches to identify mechanisms underlying CRPC in an aggregate cohort of 272 prostate cancer patients. We analyzed structural rearrangements at the genome-wide level and carried out a detailed structural rearrangement analysis of the AR locus. We used genome engineering to perform experimental modeling of AR gene rearrangements and long-read RNA sequencing to analyze effects on expression of AR and truncated AR variants (AR-V).
RESULTS: AR was among the most frequently rearranged genes in CRPC tumors. AR gene rearrangements promoted expression of diverse AR-V species. AR gene rearrangements occurring in the context of AR amplification correlated with AR overexpression. Cell lines with experimentally derived AR gene rearrangements displayed high expression of tumor-specific AR-Vs and were resistant to endocrine therapies, including the AR antagonist enzalutamide.
CONCLUSIONS: AR gene rearrangements are an important mechanism of resistance to endocrine therapies in CRPC. ©2020 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 31932493      PMCID: PMC7165042          DOI: 10.1158/1078-0432.CCR-19-3023

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  45 in total

1.  A hormone-DNA repair circuit governs the response to genotoxic insult.

Authors:  Jonathan F Goodwin; Matthew J Schiewer; Jeffry L Dean; Randy S Schrecengost; Renée de Leeuw; Sumin Han; Teng Ma; Robert B Den; Adam P Dicker; Felix Y Feng; Karen E Knudsen
Journal:  Cancer Discov       Date:  2013-09-11       Impact factor: 39.397

2.  Circulating Tumor DNA Genomics Correlate with Resistance to Abiraterone and Enzalutamide in Prostate Cancer.

Authors:  Matti Annala; Gillian Vandekerkhove; Daniel Khalaf; Sinja Taavitsainen; Kevin Beja; Evan W Warner; Katherine Sunderland; Christian Kollmannsberger; Bernhard J Eigl; Daygen Finch; Conrad D Oja; Joanna Vergidis; Muhammad Zulfiqar; Arun A Azad; Matti Nykter; Martin E Gleave; Alexander W Wyatt; Kim N Chi
Journal:  Cancer Discov       Date:  2018-01-24       Impact factor: 39.397

Review 3.  Androgen receptor rediscovered: the new biology and targeting the androgen receptor therapeutically.

Authors:  Charles J Ryan; Donald J Tindall
Journal:  J Clin Oncol       Date:  2011-08-22       Impact factor: 44.544

4.  Androgen Receptor Splice Variants Dimerize to Transactivate Target Genes.

Authors:  Duo Xu; Yang Zhan; Yanfeng Qi; Bo Cao; Shanshan Bai; Wei Xu; Sanjiv S Gambhir; Peng Lee; Oliver Sartor; Erik K Flemington; Haitao Zhang; Chang-Deng Hu; Yan Dong
Journal:  Cancer Res       Date:  2015-06-09       Impact factor: 12.701

5.  Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance.

Authors:  Scott M Dehm; Lucy J Schmidt; Hannelore V Heemers; Robert L Vessella; Donald J Tindall
Journal:  Cancer Res       Date:  2008-07-01       Impact factor: 12.701

6.  Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer.

Authors:  M E Taplin; G J Bubley; T D Shuster; M E Frantz; A E Spooner; G K Ogata; H N Keer; S P Balk
Journal:  N Engl J Med       Date:  1995-05-25       Impact factor: 91.245

7.  Integrative genomics viewer.

Authors:  James T Robinson; Helga Thorvaldsdóttir; Wendy Winckler; Mitchell Guttman; Eric S Lander; Gad Getz; Jill P Mesirov
Journal:  Nat Biotechnol       Date:  2011-01       Impact factor: 54.908

8.  AR intragenic deletions linked to androgen receptor splice variant expression and activity in models of prostate cancer progression.

Authors:  Y Li; T H Hwang; L A Oseth; A Hauge; R L Vessella; S C Schmechel; B Hirsch; K B Beckman; K A Silverstein; S M Dehm
Journal:  Oncogene       Date:  2012-01-23       Impact factor: 9.867

9.  Genomic correlates of clinical outcome in advanced prostate cancer.

Authors:  Wassim Abida; Joanna Cyrta; Glenn Heller; Davide Prandi; Joshua Armenia; Ilsa Coleman; Marcin Cieslik; Matteo Benelli; Dan Robinson; Eliezer M Van Allen; Andrea Sboner; Tarcisio Fedrizzi; Juan Miguel Mosquera; Brian D Robinson; Navonil De Sarkar; Lakshmi P Kunju; Scott Tomlins; Yi Mi Wu; Daniel Nava Rodrigues; Massimo Loda; Anuradha Gopalan; Victor E Reuter; Colin C Pritchard; Joaquin Mateo; Diletta Bianchini; Susana Miranda; Suzanne Carreira; Pasquale Rescigno; Julie Filipenko; Jacob Vinson; Robert B Montgomery; Himisha Beltran; Elisabeth I Heath; Howard I Scher; Philip W Kantoff; Mary-Ellen Taplin; Nikolaus Schultz; Johann S deBono; Francesca Demichelis; Peter S Nelson; Mark A Rubin; Arul M Chinnaiyan; Charles L Sawyers
Journal:  Proc Natl Acad Sci U S A       Date:  2019-05-06       Impact factor: 11.205

10.  Androgen receptor signaling regulates DNA repair in prostate cancers.

Authors:  William R Polkinghorn; Joel S Parker; Man X Lee; Elizabeth M Kass; Daniel E Spratt; Phillip J Iaquinta; Vivek K Arora; Wei-Feng Yen; Ling Cai; Deyou Zheng; Brett S Carver; Yu Chen; Philip A Watson; Neel P Shah; Sho Fujisawa; Alexander G Goglia; Anuradha Gopalan; Haley Hieronymus; John Wongvipat; Peter T Scardino; Michael J Zelefsky; Maria Jasin; Jayanta Chaudhuri; Simon N Powell; Charles L Sawyers
Journal:  Cancer Discov       Date:  2013-09-11       Impact factor: 39.397

View more
  27 in total

1.  Deep whole-genome ctDNA chronology of treatment-resistant prostate cancer.

Authors:  Cameron Herberts; Matti Annala; Joonatan Sipola; Sarah W S Ng; Xinyi E Chen; Anssi Nurminen; Olga V Korhonen; Aslı D Munzur; Kevin Beja; Elena Schönlau; Cecily Q Bernales; Elie Ritch; Jack V W Bacon; Nathan A Lack; Matti Nykter; Rahul Aggarwal; Eric J Small; Martin E Gleave; David A Quigley; Felix Y Feng; Kim N Chi; Alexander W Wyatt
Journal:  Nature       Date:  2022-07-20       Impact factor: 69.504

2.  Pyrazol-1-yl-propanamides as SARD and Pan-Antagonists for the Treatment of Enzalutamide-Resistant Prostate Cancer.

Authors:  Yali He; Dong-Jin Hwang; Suriyan Ponnusamy; Thirumagal Thiyagarajan; Michael L Mohler; Ramesh Narayanan; Duane D Miller
Journal:  J Med Chem       Date:  2020-10-23       Impact factor: 7.446

Review 3.  Patient-derived tumour models for personalized therapeutics in urological cancers.

Authors:  Arjanneke F van de Merbel; Geertje van der Horst; Gabri van der Pluijm
Journal:  Nat Rev Urol       Date:  2020-11-10       Impact factor: 14.432

4.  Androgen receptor variants: RNA-based mechanisms and therapeutic targets.

Authors:  Kiel T Tietz; Scott M Dehm
Journal:  Hum Mol Genet       Date:  2020-09-30       Impact factor: 6.150

Review 5.  Resistance to second-generation androgen receptor antagonists in prostate cancer.

Authors:  Keith T Schmidt; Alwin D R Huitema; Cindy H Chau; William D Figg
Journal:  Nat Rev Urol       Date:  2021-03-19       Impact factor: 14.432

6.  Increased transcription and high translation efficiency lead to accumulation of androgen receptor splice variant after androgen deprivation therapy.

Authors:  Tianfang Ma; Shanshan Bai; Yanfeng Qi; Yang Zhan; Nathan Ungerleider; Derek Y Zhang; Taavi Neklesa; Eva Corey; Scott M Dehm; Kun Zhang; Erik K Flemington; Yan Dong
Journal:  Cancer Lett       Date:  2021-02-06       Impact factor: 8.679

Review 7.  Overcoming oncogene addiction in breast and prostate cancers: a comparative mechanistic overview.

Authors:  Eliot B Blatt; Noa Kopplin; Shourya Kumar; Ping Mu; Suzanne D Conzen; Ganesh V Raj
Journal:  Endocr Relat Cancer       Date:  2021-02       Impact factor: 5.678

8.  Androgen receptor splice variant 7 functions independently of the full length receptor in prostate cancer cells.

Authors:  Jiaqian Liang; Liyang Wang; Larysa Poluben; Mannan Nouri; Seiji Arai; Lisha Xie; Olga S Voznesensky; Laura Cato; Xin Yuan; Joshua W Russo; Henry W Long; Myles Brown; Shaoyong Chen; Steven P Balk
Journal:  Cancer Lett       Date:  2021-07-10       Impact factor: 8.679

9.  iRGD-liposomes enhance tumor delivery and therapeutic efficacy of antisense oligonucleotide drugs against primary prostate cancer and bone metastasis.

Authors:  Jibin Guan; Hong Guo; Tang Tang; Yihan Wang; Yushuang Wei; Punit Seth; Yingming Li; Scott M Dehm; Erkki Ruoslahti; Hong-Bo Pang
Journal:  Adv Funct Mater       Date:  2021-04-10       Impact factor: 19.924

10.  AR gene rearrangement analysis in liquid biopsies reveals heterogeneity in lethal prostate cancer.

Authors:  Mark Daniel; Todd P Knutson; Jamie M Sperger; Yingming Li; Anupama Singh; Charlotte N Stahlfeld; Courtney Passow; Benjamin Auch; Joshua M Lang; Scott M Dehm
Journal:  Endocr Relat Cancer       Date:  2021-08-11       Impact factor: 5.900

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.